All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2020-10-30T12:34:11.000Z

How should we treat older patients with ALL?

By Claire Baker, Maria Kasimati
Featured
Elias Jabbour
Oct 30, 2020
Share:

Bookmark this article

During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, How should we treat older patients with ALL?

How should we treat older patients with ALL?

Jabbour starts by outlining the reasons why older patients with ALL are challenging to treat. He then goes on to discuss two newly available antibody drugs, blinatumomab and Inotuzumab, which are more tolerable in older patient populations.


More about...
AdultBlinatumomabConjugated antibodiesInotuzumab ozogamicinSOHO 2020Special populationsT-cell engagers

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
2 votes - 80 days left ...

Related articles

Add bookmark

Efficacy and safety of CAR T-cell reinfusion in children and young adults with R/R B-ALL

Here, we summarize a retrospective study evaluating the safety and efficacy of CAR T-cell reinfusion in the prevention and treatment of relapse in children and...

May 3, 2024
Add bookmark

Efficacy and safety of CAR T-cell reinfusion in children and young adults with R/R B-ALL

Here, we summarize a retrospective study evaluating the safety and efficacy of CAR T-cell reinfusion in the...

May 3, 2024
Add bookmark

“How I Treat”: Case studies on treatment approaches in children with ETP-ALL

Here, we discuss three case studies focused on the treatment approaches and management of children, adolescents, and young adults with ETP-ALL.

Mar 26, 2024
Add bookmark

“How I Treat”: Case studies on treatment approaches in children with ETP-ALL

Here, we discuss three case studies focused on the treatment approaches and management of children, adolescents, and young...

Mar 26, 2024
Add bookmark

Geriatric hematology in low-resource settings: Improving care for older people through the implementation of geriatric hematology programs

Currently, more than half of the 700 million people aged 65 years or older live in low- and middle-income...

Oct 22, 2021
Add bookmark

Geriatric hematology in low-resource settings: Improving care for older people through the implementation of geriatric hematology programs

Currently, more than half of the 700 million people aged 65...

Oct 22, 2021
Add bookmark

Development of childhood B-ALL, triggering factors, and prospective treatments

Childhood B-cell acute lymphoblastic leukemia (B-ALL), also termed B-cell precursor ALL, is a malignant disease characterized by the rapid expansion of clonal blast cells...

Mar 18, 2021
Add bookmark

Development of childhood B-ALL, triggering factors, and prospective treatments

Childhood B-cell acute lymphoblastic leukemia (B-ALL), also termed B-cell precursor ALL, is a malignant disease...

Mar 18, 2021

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox